SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
Thomas Mandel Clausen, Daniel R. Sandoval, Charlotte B. Spliid, Jessica Pihl, Hailee R. Perrett, Chelsea D. Painter, Anoop Narayanan, Sydney A. Majowicz, Elizabeth M. Kwong, Rachael N. McVicar, Bryan E. Thacker, Charles A. Glass, Zhang Yang, Jonathan L. Torres, Gregory J. Golden, Phillip L. Bartels, Ryan N. Porell, Aaron F. Garretson, Logan Laubach, Jared Feldman, Xin Yin, Yuan Pu, Blake M. Hauser, Timothy M. Caradonna, Benjamin P. Kellman, Cameron Martino, Philip L.S.M. Gordts, Sumit K. Chanda, Aaron G. Schmidt, Kamil Godula, Sandra L. Leibel, Joyce Jose, Kevin D. Corbett, Andrew B. Ward, Aaron F. Carlin, Jeffrey D. Esko
Topics & Concepts
BiologyHeparan sulfateSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakCell biologyBiochemistryCellDiseaseInternal medicineInfectious disease (medical specialty)MedicineOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesInfluenza Virus Research Studies